A Self-Improving Prediction System

EU AI Act GPAI enforcement powers officially take legal effect on August 2, 2026 as scheduled

The August 2, 2026 date is codified in Article 113 of the EU AI Act. The Commission gains powers to request documentation, conduct evaluations, require compliance measures, and impose fines (up to 3% global annual turnover or 15 million euros). Absent an extraordinary legal challenge or legislative amendment—essentially impossible in this timeframe—this takes effect automatically on the scheduled date. The 97% leaves minimal residual for extreme circumstances such as a successful emergency injun

Brazil's October 4, 2026 presidential first round fails to produce a candidate with more than 50% of valid votes, requiring a second-round runoff on October 25.

Lula polling at 41-43% in first-round intentions — well below the 50%+1 threshold for first-round victory. All three of Brazil's most recent presidential elections went to a second round. Flávio Bolsonaro at 28-34%. The fragmented right-wing field and Lula's below-50% polling make a runoff near-certain. Only scenario against: a late catastrophic collapse of all right-wing candidates, extremely unlikely.

No P&I club reinstates Hormuz transit insurance coverage for mainstream (non-shadow) fleet by July 31

Second merchant vessel struck June 27 resets the zero-incident clock. P&I clubs require sustained normal vessel movement before underwriting at scale. Minimum zero-incident period = 30 days = earliest possible reconsideration July 27. Mine clearance (30-day MOU commitment from June 14) still ongoing with no completion confirmed. Doha talks failed. Physical prerequisites cannot all be met by July 31. Near-certain outcome.

Orca-T FDA action letter (approval or CRL) issued by July 10 2026

PDUFA July 6 is confirmed active. FDA has 4-day buffer to July 10. FDA virtually always acts within 1-3 days of PDUFA date; the only scenario for non-action would be an extraordinary late amendment or legal challenge. RMAT designation signals close FDA engagement. +calibration +11pp applied to already-high base.

Orca-T FDA takes action (approval or Complete Response Letter) by July 10 2026 without a further PDUFA extension.

PDUFA date is July 6, only 14 days away. Manufacturing expansion announced June 15 (East Coast Princeton site, tripled West Coast workforce) signals pre-launch readiness. FDA extended once (CMC major amendment); second extension from this point is rare (~5-10% base rate). Calibration +11pp applied to near-certainty base; upper ceiling is 95%.

FDA will issue an action letter (approval or CRL) for Orca-T by July 10 2026 (within 4 days of PDUFA)

PDUFA July 6 is a statutory deadline; FDA overwhelmingly acts on or before PDUFA dates. 4-day buffer accounts for minor calendar slippage. No extension signals as of June 23. FDA explicitly said no additional clinical data needed — review on track. Combined with manufacturing inspection signals, the probability of any further delay beyond July 10 is extremely low (<5%).

FDA issues action letter (approval OR CRL) for Orca-T by July 10 2026

PDUFA date July 6 is legally binding; FDA acts on or before PDUFA date in >98% of cases. Four-day buffer to July 10 further reduces uncertainty. Consistent with prior predictions at 0.93-0.95. No signals of additional PDUFA extension. Only extreme scenario (e.g., agency shutdown or second major amendment) would prevent action.

FDA issues action letter (approval or CRL) for Vera Therapeutics atacicept by July 10 2026

PDUFA July 7. FDA typically issues action letters on or around PDUFA date. No PDUFA extension signals. 3-day buffer after PDUFA date. Near-certain administrative outcome. 5% residual for extreme unlikely scenario of late extension.

John Ternus officially assumes Apple CEO role on or before September 1, 2026

Apple announced April 20, 2026 that Tim Cook transitions to Executive Chairman and John Ternus becomes CEO "effective September 1, 2026" per SEC Form 8-K filing. This is a board-approved, disclosed corporate action with no reported opposition or complication. Residual uncertainty (~7%): extraordinary event (health, board reversal, regulatory block) that causes delay or cancellation.

EU AI Act GPAI enforcement powers are fully in application and the Commission can exercise supervision against GPAI providers by August 5, 2026

Statutory calendar-driven event. EU AI Act specifies August 2, 2026 as the date Commission enforcement powers over GPAI models activate, following a one-year adjustment period from August 2025. This is legislative statute, not event-triggered. Near-certain unless extraordinary legislative reversal occurs. Cornelius: calendar-driven events ~95% (slight discount for unprecedented EU institutional failure).

10-year US Treasury yield stays above 4.40% on July 9, 2026

10Y at 4.50% on Jul 7-8. FOMC minutes released Jul 8 were hawkish (9/18 officials projected hike). May CPI was 4.2% YoY with 23.5% energy surge — ongoing inflation concerns keep yields elevated. 4.40% is -10bps from current; would require material risk-off flight-to-safety. Iran war ongoing but already priced; applying mild economics|immediate conservatism from calibration notes.

VIX closes below 17 on July 9, 2026

VIX at 16.13 on Jul 8; market has absorbed Iran active-war news with remarkable calm. Cornelius: VIX at 16 post-war is a signal that war premium has fully collapsed — stability mode. No new compound shock catalyst visible today. A breach above 17 would require a fresh escalation event.

Nasdaq Composite closes in positive territory on July 9, 2026

Nasdaq turned green Jul 8 with semis/tech leading a bounce. However NVDA premarket -1.62% ($193.78) tempers enthusiasm for a follow-through. Positive macro futures partially offset by semi weakness. Near coin-flip; calibration note for economics|immediate degrading does not apply directly but general conservatism warranted.

NVIDIA (NVDA) closes above $190 on July 9, 2026

NVDA premarket at $193.78 (-1.62% from $196.97 close). Structural AI demand (AWS hypergrowth rule per Cornelius) supports medium-term; $190 is ~2% below premarket price. Intraday recovery possible given broad market positive tone. Applying tech|medium conservatism (Brier degrading 0.158→0.236) per calibration notes — lowered from 0.70.

WTI crude oil front-month futures stay above $72 per barrel on July 9, 2026

WTI settled $73.52 on Jul 8 (+4.4%). Iran-US active war; Trump declared ceasefire over, US revoked Iran oil sale authorization. Cornelius: war premium re-prices before physics — caution on floor confidence, cap at 55-65%. Any de-escalation signal (even verbal) could bring rapid -3-5% move. Setting 0.65 per Cornelius guidance.

Brent crude oil front-month futures stay above $76 per barrel on July 9, 2026

Brent settled $78.02 on Jul 8 (+5.2%), with intraday high $79.93. Iran active war, Hormuz mines (80 remain), US revoked Iran oil waiver. Cornelius war premium collapse speed caution — cap at 55-65%. $76 requires -2.6% decline from settle. Credible if any de-escalation headlines emerge during Asia/Europe trading.

EUR/USD stays above 1.120 at close on July 9, 2026

Hawkish minutes could push EUR/USD from 1.143 toward 1.130, but 1.120 requires a 2%+ decline over two days. Cornelius cautions against >60% on EUR/USD above X in post-hawkish window; however 1.120 is sufficiently far below current (2% drop) to warrant moderate confidence. A 2% EUR/USD decline would be outsized for a single-week move without a concurrent EUR-specific negative catalyst. Capping at 0.65 to respect Cornelius guidance.

WTI crude oil price stays below $73.00 at close on July 9, 2026

WTI at ~$68.25; $73 requires ~7% rally from current levels. OPEC+ 188K bpd August increase announcement is structurally bearish. Hawkish FOMC → USD strength → mild oil headwind. Hormuz incident would need to dramatically escalate for WTI to reach $73+. Cornelius bimodal framework: de-escalation continuation mode (deal holding) places WTI in $75-88 range but from higher baseline; from current $68 the modal distribution does not support $73+ without re-escalation.